Investing.com - Verrica Pharmaceuticals (NASDAQ: VRCA) reported fourth quarter EPS of $-0.53, $0.05 better than the analyst estimate of $-0.58. Revenue for the quarter came in at $1.99M versus the consensus estimate of $941.92K.
Verrica Pharmaceuticals's stock price closed at $5.72. It is up 49.74% in the last 3 months and down -21.74% in the last 12 months.
Verrica Pharmaceuticals saw 0 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Verrica Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, Verrica Pharmaceuticals's Financial Health score is "fair performance".
Check out Verrica Pharmaceuticals's recent earnings performance, and Verrica Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar